Biogen Stock Is Down on a Report That Few Have Received Its New Alzheimer’s Therapy

3 years ago 332

This transcript is for your personal, non-commercial usage only. To bid presentation-ready copies for organisation to your colleagues, clients oregon customers sojourn http://www.djreprints.com.

https://www.barrons.com/articles/biogen-stock-down-alzheimers-51632319432

Sept. 22, 2021 10:04 americium ET

Order Reprints
Print Article

Investors’ deepest worries astir Biogen‘s arguable Alzheimer’s therapy seemed to beryllium coming existent aboriginal Wednesday. Health-care quality tract STAT revealed that lone astir 100 patients had received Biogen‘s recently approved Alzheimer’s illness therapy Aduhelm arsenic of Sept. 11.

Investors had expected the motorboat to spell slowly, and Biogen (ticker: BIIB) has tried to bounds expectations successful caller months. Still, the STAT study suggests that the rollout is going adjacent worse than investors had thought.

According...

Read Entire Article